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Abstract
This review focuses on recent advances in the treatment of aortic-valve stenosis with special
emphasis on medical treatment for preventing disease progression, and on novel surgical and
percutaneous approaches.
Introduction and context
Aortic stenosis (AS) is the most common native valve
disease at present. It is the third most common
cardiovascular disease after hypertension and coronary
artery disease.
The first epidemiologic study evaluating the prevalence
of AS in Finland revealed the prevalence of severe AS
(AVA ≤0.8 cm
2) in 2.9% of elderly over 75 years of age,
mild aortic valve calcification in 40% and severe
calcification in 13% [1].
Currently, AS is also the second most common indica-
tion for cardiac surgery, and the most common indica-
tion for valve surgery. In the European registry for
valvular heart disease it was found that AS constitutes
43% of all valve diseases [2]. There are two important
reasons for this high prevalence: first, about 2% of the
population is born with a bicuspid aortic valve; and
second, the ageing population is reaching the stage
where significant degenerative aortic valve disease is
developing. Although AS is associated with substantial
clinical consequences, until recently there was no
effective therapy to treat it other than surgical aortic
valve replacement.
Recent advances
Effect of statins on the progression of aortic valve stenosis
Recent advances in the pathophysiology of AS indicate
that calcific AS is an active disease process that resembles
atherosclerosis and shares the same risk factors. An active
atherosclerotic-type pathophysiology involving oxida-
tive stress, inflammation, and endothelial dysfunction in
aortic valves has been induced in mice by hypercholes-
terolaemia, and inhibited by administering HMG-CoA
reductase inhibitors (statins) [3]. Consequently, a
hypothesis was developed proposing that AS could be
a preventable disease, or at least that its progression
could be slowed by medical interventions that are
effective in slowing or reversing atherosclerosis. Several
retrospective studies have suggested that statin therapy
may slow the progression of AS as measured by
the annual change per year in aortic valve area.
Novaro et al. [4], for example, found that the decrease in
aortic valve area for a group not treated with statins was
0.11±0.18 cm
2, compared to 0.06±0.16 cm
2 for those
treated with statins (P = 0.030).
These findings and existing experimental data were the
driving force to conduct prospective randomized studies
to resolve this important question. In the past several
years, three completed prospective studies on the effect
of statin therapy on AS progression have been published.
The first prospective (non-randomized), open-label
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Endothelium (RAAVE) study [5]. In this study, echocar-
diographic, serum lipid, and inflammatory marker
determinations were used at baseline and every 6
months for 18 months to evaluate outcomes in 121
patients with asymptomatic moderate to severe AS
(aortic valve area 1.0-1.5 cm
2) who were treated with
or without rosuvastatin. This study suggested that
rosuvastatin treatment slowed the progression of AS,
including hemodynamic indices of progression. It was
the first prospective study that showed the potential of
medical treatment to slow progression of asymptomatic
AS. However, this study was limited by being a non-
randomized, observational study.
The second important study was the Scottish Aortic
Stenosis and Lipid Lowering Trial, Impact on Regression
(SALTIRE) [6], a randomized, double blind, placebo-
controlled trial with a median follow-up of 25 months.
In this study, 155 patients with calcific AS and aortic jet
velocity <2.5 m/s were treated with either atorvastatin
80 mg/day (n = 77) or placebo (n = 78). In contrast to
the RAAVE study, it did not detect a short-term impact of
statins on echocardiographic progression of AS or on
aortic valve calcium score. The SALTIRE investigators
concluded that intensive lipid-lowering therapy did not
slow the progression of calcific AS or induce its
regression. However, the investigators could not exclude
a small reduction in the rate of AS progression or a
significant reduction in major clinical endpoints. Also,
nearly 25% of the study population in the atorvastatin
group and 22% in the placebo group had severe AS to
begin with and in these patients the disease stage may
have been too advanced to be affected by statin therapy
within the study's duration.
The third study, the Simvastatin and Ezetimibe in Aortic
Stenosis (SEAS) study [7], was a randomized, double
blind trial involving 1,873 patients with mild to
moderate asymptomatic AS. The patients received either
40 mg simvastatin plus 10 mg ezetimibe or placebo
daily. The primary outcome was a composite outcome of
combined aortic-valve events and ischemic events.
During a median follow-up of 52.2 months, simvastatin
and ezetimibe did not reduce the composite outcome.
Statin therapy reduced the incidence of ischemic
cardiovascular events but not events related to AS.
Interestingly, cancer occurred more frequently in the
simvastatin-ezetimibe group.
Apicoaortic conduit bypass surgery
Conventional aortic valve replacement surgery mandates
the use of cardiopulmonary bypass, ascending aortic
crossclamping, aortotomy, debridement of the diseased
valve, and cardioplegic cardiac arrest. An alternative
surgical approach has been suggested in which a conduit
containing a prosthetic valve relieves AS by shunting
blood from the apex of the left ventricle to the
descending thoracic aorta (apicoaortic conduit bypass
surgery). This surgical approach has been applied
sporadically to high-risk adult patients with acquired
AS, with just over 100 reported cases in the literature [8].
Recently, Gammie et al. [9] described a series of 31 high-
risk AS patients treated with apicoaortic conduit bypass
surgery; 22 patients (71%) were undergoing re-operation
with patent coronary bypass grafts, and five (16%) had a
porcelain ascending aorta. Postoperative echocardio-
graphic assessment demonstrated that a mean of 72%
of cardiac output flowed through the bypass conduit.
The relief of left ventricular outflow tract obstruction was
commonly associated with a downgrading of the degree
of mitral regurgitation and left ventricular function was
preserved. Importantly, in this high-risk patient group,
surgical complications were uncommon (only one
patient required temporary postoperative hemodialysis
and only one patient experienced stroke); however,
median postoperative survival was only 870 days, similar
to the natural history of unoperated symptomatic AS.
This approach is an addition to the armamentarium of
therapies for symptomatic AS patients with a high
surgical risk and will be further examined in the future.
Percutaneous aortic valve implantation
As many as one-third of elderly patients with sympto-
matic AS are not referred for surgery, usually
due to high surgical risk or patient refusal. Unfortu-
nately, percutaneous balloon valvuloplasty is unsatisfac-
tory with high recurrence rates. In 2002, Cribier
performed the first percutaneous aortic valve implanta-
tion (PAVI), opening a new era in AS management
Early implants were performed using Cribier-Edwards
valves (Edwards Lifesciences, Irvine, California, USA),
which are composed of three leaflets of animal
pericardium sutured to a balloon-inflated stent 23 or
et al
Edwards valve, 23 with the antegrade approach and four
with the retrograde approach. All were elderly, with
severe co-morbidities, and ineligible for conventional
therapy (‘no-option’ patients). After the procedure, mean
valve area increased to 1.7 cm
2, yielding a small but
significant improvement in global function of the left
ventricle. Importantly, there were no deaths directly
related to the procedure. Afterwards, Webb et al. [12]
reported the outcome of the first 50 high surgical risk
severe symptomatic AS patients treated with the Edwards
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[10].
26 mm in diameter. Cribier . [11] described
the first 27 patients treated by PAVI with thevalve implant in Vancouver, Canada, all with the
retrograde approach. PAVI was successful in 86% of
patients. On long-term follow-up of 1 year, and up to 2
years, there was not a single case of valve restenosis or
malfunction. The mortality rate was 12% in the first
month after the procedure, which was lower than the
28% predicted mortality according to the patients'
preprocedural EuroSCOREs (European System for Car-
diac Operative Risk Evaluation). Another important
finding in the study of Webb et al. was the difference
between patients treated at the beginning of the learning
curve and those treated later in terms of procedural
success (76 versus 96%) and 1-month mortality (16
versus 8%), indicating the importance of physician
experience. Currently, more than 1,000 patients have
been treated using the PAVI technique and the Cribier-
Edwards valve, which was slightly modified and is now
The CoreValve system for percutaneous aortic valve
replacement (CoreValve Inc, Irvine, CA, USA), also called
ReValving technology, is composed of a valve encircled
by a 50–53 mm-long frame (depending on valve size)
(Figure 2). The CoreValve is self-expandable and intended
for mitigation of paravalvular leak and increased
durability, although post implantation frame remodel-
ling by means of balloon expansion during use is not
uncommon [13]. The possibility to remodel the system
after implantation may decrease the risk of perivalvular
leak. Because of the self-expanding feature, the suggested
use of the system might be extendable to patients who
underwent prior surgical biologic valve replacement
(‘ReDo™’ procedure) [14]. If physicians were able to
effectively perform PAVI inside a degenerative implanted
biologic valve, the use of biologic valves for aortic valve
replacement may increase, because valve malfunction
could be treated without the need for redoing surgery.
The current (third generation) model has been signifi-
cantly improved and its delivery catheter has a diameter
of only 18Fr. The implantation results of the second- and
third-generation systems in 86 patients in several centers
in Germany and Canada have been published [15]. Most
patients were women, selected because of the small size
of the implanted valve, with a mean age of 82 years and a
high mean EuroSCORE of 21.7%. The procedural success
rate was 88%. There was a dramatic improvement in
hemodynamic parameters, including an increase in valve
area to 1.7 cm
2. Valve regurgitation worsened in only a
minority of cases. In the first month after the procedure
the mortality rate was 12%; half of these deaths occurred
in the first 2 days. Stroke occurred in 10%. Furthermore,
urgent cardiac surgery to release the device was necessary
in 6% of patients. At the time of preparing the present
review, more than 3,000 patients had been treated with
the CoreValve framed valve. According to currently
unpublished results, the procedural success rate for the
18Fr device is 98%, with only 0.7% of patients requiring
aortic valve replacement surgery in the first post-
procedural month.
The transapical approach requires a team consisting of
cardiac surgeons and interventional cardiologists
[16,17]. After a left anterolateral intercostal incision is
made to expose the cardiac apex, the delivery system is
inserted into the left ventricular cavity and the valve is
implanted (Figure 3). This approach is more invasive
than those discussed above. The transapical approach
has several important advantages. First, there is no
delivery of the system via the peripheral vessels, the
ascending aorta, or several cardiac chambers, with
attendant risks. Second, unlike conventional valve
replacement, there is no need for cardiopulmonary
bypass or manipulation in the ascending aorta, poten-
tially decreasing the risk of periprocedural stroke. In a
recent report on their experience with this method in
patients with severe co-morbidity (EuroSCORE 31%),
Walther et al. [18] described no procedural failures and
excellent hemodynamics in all cases after severalmonths'
follow-up. There were no procedure-related deaths or
strokes. Recently, Zierer et al. [19] reported on 26 patients
treated with this approach. The EuroSCORE-predicted
risk for mortality was 36.5%. All valves were successfully
deployed at the target and there were only minor
Figure 1. The Edwards SAPIEN transcatheter heart valve
A bovine pericardial valve is sewn within a stainless steel frame. Image
provided by Edwards Lifesciences, Irvine, California.
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called the Edwards SAPIEN valve (Figure 1).
Nparavalvular leakages. Thirty-day mortality was 15%
(n = 4). There were two cases of conversion to open
surgery. In two patients, the left main stem was partially
obstructed by the native valve and required stent
angioplasty. During this past year, this approach has
been used in several centers worldwide.
Implications for clinical practice
Effect of statins on the progression of aortic valve stenosis
Several retrospective and one non-randomized study
(RAAVE) have suggested that statin therapy may slow the
progression of AS, but the only two available large
prospective randomized double blinded studies did not
show any effect of high-dose statin therapy on AS
progression. Therefore, the data we currently have are
contradictory but tend to suggest that statin therapy has
no significant effect on the natural history of AS.
However, we should await the results of larger rando-
mized studies (ASTRONOMER, AORTICA 1, STAAT and
STOP-AS) with longer follow-up, which hopefully will
resolve this important issue. Importantly, most of these
studies were performed on patients with moderate or
severe AS. It might be that statin therapy may be more
effective if it is started at a very early stage of the disease
when patients have only mild AS or even only non-
obstructive aortic valve calcification.
Percutaneous aortic valve implantation
Although still in its early stages, and not yet sufficiently
viable to replace conventional methods in low-risk
patients, percutaneous treatment of AS holds promise
for providing symptomatic relief and, possibly, longevity
to patients who are ineligible for surgery due to their
high surgical risk. Preliminary studies show that PAVI is
both feasible and effective in elderly patients with AS in
the short and medium term. However, the procedure is
still associated with significant adverse effects and
mortality, and the long-term results are still unknown.
Therefore, the procedure is not yet ready to replace
conventional surgical aortic valve replacement in low
risk patients and at this time is reserved for high surgical
risk candidates.
Abbreviations
Figure 2. The CoreValve device
A self-expanding Nitinolframe within which ismounted a trileaflettissuevalve.
Image provided by CoreValve Inc, Irvine, California.
Figure 3. Illustration of transapical valve implantation
Image provided by Edwards Lifesciences, Irvine, California.
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